WallStreetZenWallStreetZen

NASDAQ: ASMB
Assembly Biosciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ASMB stock forecasts and price targets.

Forecast return on equity

Is ASMB forecast to generate an efficient return?
Company
-257.39%
Industry
71.74%
Market
80.3%
ASMB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ASMB forecast to generate an efficient return on assets?
Company
-70%
Industry
30.97%
ASMB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ASMB earnings per share forecast

What is ASMB's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$12.65
Avg 2 year Forecast
-$13.45
Avg 3 year Forecast
-$14.31

ASMB revenue forecast

What is ASMB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$24.2M
Avg 2 year Forecast
$29.0M
Avg 3 year Forecast
$27.2M

ASMB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ASMB$15.13N/AN/A
ANTX$2.79$5.00+79.21%Hold
VSTM$3.32$17.88+438.40%Strong Buy
SGMO$0.40$3.50+781.61%Buy
TIL$12.65$20.33+60.74%Buy

Assembly Biosciences Stock Forecast FAQ

What is ASMB's earnings growth forecast for 2024-2026?

(NASDAQ: ASMB) Assembly Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Assembly Biosciences's earnings in 2024 is -$51,355,000.On average, 1 Wall Street analyst forecast ASMB's earnings for 2024 to be -$69,743,346, with the lowest ASMB earnings forecast at -$69,743,346, and the highest ASMB earnings forecast at -$69,743,346. On average, 1 Wall Street analyst forecast ASMB's earnings for 2025 to be -$74,153,993, with the lowest ASMB earnings forecast at -$74,153,993, and the highest ASMB earnings forecast at -$74,153,993.

In 2026, ASMB is forecast to generate -$78,895,437 in earnings, with the lowest earnings forecast at -$78,895,437 and the highest earnings forecast at -$78,895,437.

If you're new to stock investing, here's how to buy Assembly Biosciences stock.

What is ASMB's revenue growth forecast for 2024-2026?

(NASDAQ: ASMB) Assembly Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.24%.

Assembly Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ASMB's revenue for 2024 to be $133,422,054, with the lowest ASMB revenue forecast at $133,422,054, and the highest ASMB revenue forecast at $133,422,054. On average, 1 Wall Street analysts forecast ASMB's revenue for 2025 to be $160,106,464, with the lowest ASMB revenue forecast at $160,106,464, and the highest ASMB revenue forecast at $160,106,464.

In 2026, ASMB is forecast to generate $149,741,445 in revenue, with the lowest revenue forecast at $149,741,445 and the highest revenue forecast at $149,741,445.

What is ASMB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ASMB) forecast ROA is -70%, which is lower than the forecast US Biotechnology industry average of 30.97%.

What is ASMB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ASMB) Assembly Biosciences's current Earnings Per Share (EPS) is -$10.48. On average, analysts forecast that ASMB's EPS will be -$12.65 for 2024, with the lowest EPS forecast at -$12.65, and the highest EPS forecast at -$12.65. On average, analysts forecast that ASMB's EPS will be -$13.45 for 2025, with the lowest EPS forecast at -$13.45, and the highest EPS forecast at -$13.45. In 2026, ASMB's EPS is forecast to hit -$14.31 (min: -$14.31, max: -$14.31).

What is ASMB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ASMB) forecast ROE is -257.39%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.